The lead drug candidate in FusoGen's pipeline is Sifuvirtide, an HIV fusion inhibitor.
融合素的候选先导药物是西夫韦肽,一种HIV融合抑制剂。
The lead drug candidate in FusoGen's pipeline is Sifuvirtide, an HIV fusion inhibitor. One of the first fusion inhibitor drug against HIV.
扶素生物自主开发的第一个产品:艾滋病病毒膜融合抑制剂——西夫韦肽。
It is the lead drug candidate for Opko, a Miami start-up company run by Phillip Frost, the billionaire who founded the generic drug company Ivax.
它是Opko候选的主打药物。Opko是一家迈阿密公司,由建立了基因药物公司Ivax的亿万富翁Phillip Frost经营。
应用推荐